See the DrugPatentWatch profile for ruxolitinib

Ruxolitinib, a medication used to treat certain types of blood cancer and bone marrow disorders, is available under the brand name Jakavi, which is manufactured by Novartis. However, the question asks about the availability of ruxolitinib under the brand of Apotex, a well-known pharmaceutical company.

Upon researching, I found that Apotex does indeed manufacture and distribute ruxolitinib in its generic form. According to the [DrugPatentWatch.com](https://www.drugpatentwatch.com/drugs/ruxolitinib), ruxolitinib has been approved by the FDA and is available in the market since 2012. Apotex received approval for its generic ruxolitinib tablets in 2019, which is equivalent to Jakavi's 5 mg, 10 mg, 15 mg, and 20 mg dosage strengths.

Therefore, it is clear that Apotex does offer ruxolitinib as a generic medication, equivalent to Jakavi, in various dosage strengths.

Sources:

* [DrugPatentWatch.com](https://www.drugpatentwatch.com/drugs/ruxolitinib)